HSV-1 Amplicon Vectors Launch the Production of Heterologous Rotavirus-like Particles and Induce Rotavirus-specific Immune Responses in Mice

Laimbacher, Andrea S.; Esteban, Laura Emilia; Castello, Alejandro; Cerfoglio, Juan Carlos Abdusetir; Argüelles, Marcelo Horacio; Glikmann, Graciela; D'antuono, Alejandra Lorena; Mattion, Nora; Berois, Mabel; Arbiza, Juan; Hilbe, Monika; Schraner, Elisabeth M.; Seyffert, Michael; Dresch, C; Epstein, Alberto L.; Ackermann, Mathias; Fraefel, Cornel

doi:10.1038/mt.2012.108

Cited by 26 publications

(25 citation statements)

References 50 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Herpesviruses are important mammalian pathogens that cause acute and chronic infections and can persist in the hosts for life. Example herpes virus vaccine vectors are human simplex virus-1 (HSV-1) [23] and cytomegalovirus (CMV) [24, 25]. …”

Section: Resultsmentioning

confidence: 99%

Vaxvec: The first web-based recombinant vaccine vector database and its data analysis

Deng

Martin

Patil

et al. 2015

Vaccine

View full text Add to dashboard Cite

A recombinant vector vaccine uses an attenuated virus, bacterium, or parasite as the carrier to express a heterologous antigen(s). Many recombinant vaccine vectors and related vaccines have been developed and extensively investigated. To compare and better understand recombinant vectors and vaccines, we have generated Vaxvec (http://www.violinet.org/vaxvec), the first web-based database that stores various recombinant vaccine vectors and those experimentally verified vaccines that use these vectors. Vaxvec has now included 59 vaccine vectors that have been used in 196 recombinant vector vaccines against 66 pathogens and cancers. These vectors are classified to 41 viral vectors, 15 bacterial vectors, 1 parasitic vector, and 1 fungal vector. The most commonly used viral vaccine vectors are double-stranded DNA viruses, including herpesviruses, adenoviruses, and poxviruses. For example, Vaxvec includes 63 poxvirus-based recombinant vaccines for over 20 pathogens and cancers. Vaxvec collects 30 recombinant vector influenza vaccines that use 17 recombinant vectors and were experimentally tested in 7 animal models. In addition, over 60 protective antigens used in recombinant vector vaccines are annotated and analyzed. User-friendly web-interfaces are available for querying various data in Vaxvec. To support data exchange, the information of vaccine vectors, vaccines, and related information is stored in the Vaccine Ontology (VO). Vaxvec is a timely and vital source of vaccine vector database and facilitates efficient vaccine vector research and development.

show abstract

Section: Resultsmentioning

confidence: 99%

Vaxvec: The first web-based recombinant vaccine vector database and its data analysis

Deng

Martin

Patil

et al. 2015

Vaccine

View full text Add to dashboard Cite

show abstract

“…The wheel‐like VP2/6 double‐layered virus‐like particle has also been produced by employing an Encephalomyocarditis virus (EMCV)‐derived internal ribosomal entry site element, whereby VP2 and VP6 proteins were co‐expressed in stably transformed Drosophila melanogaster Schneider 2 (S2) cells . In another study, herpes simplex virus type 1 amplicon vectors were employed for the production of RV‐VLPs in mammalian cells . These amplicon vectors co‐expressed RV genes VP2, VP6, and VP7 for the production of RV‐VLPs in vector‐infector mammalian cells (Vero 2‐2 cells).…”

Section: Rotavirus Virus‐like Particlesmentioning

confidence: 99%

“…These amplicon vectors co‐expressed RV genes VP2, VP6, and VP7 for the production of RV‐VLPs in vector‐infector mammalian cells (Vero 2‐2 cells). The resultant RV‐VLPs were found to induce a potent immune response against RV where both systemic IgG and fecal IgA were detected in mice . Escherichia coli were also employed as a production system for single and double‐layered RV‐VLPs (dl2/6‐VLPs).…”

Section: Rotavirus Virus‐like Particlesmentioning

confidence: 99%

“…109 In another study, herpes simplex virus type 1 amplicon vectors were employed for the production of RV-VLPs in mammalian cells. 110 These amplicon vectors co-expressed FIGURE 2 Schematic representation of production of non-enveloped and enveloped VLPs. A, Production of non-enveloped VLPs by expressing one or more pathogen component in an appropriate expression system.…”

Section: Virus-like Particle (Vlp) -The Technologymentioning

confidence: 99%

“…The resultant RV-VLPs were found to induce a potent immune response against RV where both systemic IgG and fecal IgA were detected in mice. 110 Escherichia coli were also employed as a production system for single and double-layered RV-VLPs (dl2/6-VLPs). The resultant RV-VLPs had better thermal stability, antigenicity, and protective efficacy in mice.…”

Section: Virus-like Particle (Vlp) -The Technologymentioning

confidence: 99%

See 2 more Smart Citations

Rotavirus virus‐like particles (RV‐VLPs) vaccines: An update

Changotra

Vij

2017

Reviews in Medical Virology

View full text Add to dashboard Cite

Rotaviruses (RVs) cause over 0.2 million deaths annually and are reported to be the foremost cause of gastroenteritis in infants and children worldwide. Vaccination against RVs is the most successful and unsurpassed strategy to combat infection to date. Although the 2 current vaccines, Rotarix and RotaTeq, have dramatically reduced the disease burden, still there is a need for new vaccines. In this context, RV virus-like particles (RV-VLPs) represent potential vaccine candidates as they are noninfectious and effective nonreplicating immunogens that may reduce the risk of side effects related to the conventional vaccines. VLPs being conformationally similar to the parent virus are highly immunogenic and hence provide enhanced protection and better serotype coverage. In this review, we have highlighted the various advantages and the implications of RV-VLPs, discussed the general strategies employed for their production, and talked about the recent developments made in this regard. Overall, the review emphasizes the probable utility of RV-VLPs in eradicating the highly widespread RVs.

show abstract

HSV-1 Amplicon Vectors as Genetic Vaccines

Meier

Laimbacher

2014

Methods in Molecular Biology

View full text Add to dashboard Cite

HSV-1 amplicon vectors have been used as platforms for the generation of genetic vaccines against both DNA and RNA viruses. Mice vaccinated with such vectors encoding structural proteins from both foot-and-mouth disease virus and rotavirus were partially protected from challenge with wild-type virus (D'Antuono et al. Vaccine 28: 7363-7372, 2010; Laimbacher et al. Mol Ther 20: 1810-1820, 2012), indicating that HSV-1 amplicon vectors are attractive tools for the development of complex and safe genetic vaccines. This chapter describes the use of HSV-1 amplicon vectors that encode individual or multiple viral structural proteins from a polycistronic transgene cassette in mammalian cells. More precisely, amplicon vectors that encode multiple structural viral proteins support the in situ production of viruslike particles (VLPs) in vector-infected cells. The expression of the viral genes is confirmed by Western blot and immune fluorescence analysis, and the generation of VLPs in vector-infected cells is demonstrated by electron microscopy.

show abstract

HSV-1 Amplicon Vectors Launch the Production of Heterologous Rotavirus-like Particles and Induce Rotavirus-specific Immune Responses in Mice

Cited by 26 publications

References 50 publications

Vaxvec: The first web-based recombinant vaccine vector database and its data analysis

Vaxvec: The first web-based recombinant vaccine vector database and its data analysis

Rotavirus virus‐like particles (RV‐VLPs) vaccines: An update

HSV-1 Amplicon Vectors as Genetic Vaccines

Contact Info

Product

Resources

About